BioArctic AB (publ) (STO:BIOA.B)
332.80
+0.40 (0.12%)
Feb 3, 2026, 3:15 PM CET
BioArctic AB Employees
BioArctic AB had 122 employees as of September 30, 2025. The number of employees increased by 18 or 17.31% compared to the same quarter last year.
Employees
122
Change
18
Growth
17.31%
Revenue / Employee
15.71M SEK
Profits / Employee
8.19M SEK
Market Cap
29.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 122 | 18 | 17.31% |
| Jun 30, 2025 | 119 | 23 | 23.96% |
| Mar 31, 2025 | 116 | 26 | 28.89% |
| Dec 31, 2024 | 107 | 19 | 21.59% |
| Sep 30, 2024 | 104 | 21 | 25.30% |
| Jun 30, 2024 | 96 | 21 | 28.00% |
| Mar 31, 2024 | 90 | 21 | 30.43% |
| Dec 31, 2023 | 88 | 27 | 44.26% |
| Sep 30, 2023 | 83 | 27 | 48.21% |
| Jun 30, 2023 | 75 | 19 | 33.93% |
| Mar 31, 2023 | 69 | 14 | 25.45% |
| Dec 31, 2022 | 61 | 12 | 24.49% |
| Sep 30, 2022 | 56 | 7 | 14.29% |
| Jun 30, 2022 | 56 | 9 | 19.15% |
| Mar 31, 2022 | 55 | 8 | 17.02% |
| Dec 31, 2021 | 49 | 4 | 8.89% |
| Sep 30, 2021 | 49 | 4 | 8.89% |
| Jun 30, 2021 | 47 | 2 | 4.44% |
| Mar 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Camurus AB | 280 |
| Hansa Biopharma AB | 133 |
| BioInvent International AB | 124 |
| Egetis Therapeutics AB | 40 |
| Diamyd Medical AB | 39 |
| Vicore Pharma Holding AB | 36 |
| Genovis AB (publ.) | 36 |
| Saniona AB | 31 |
BioArctic AB News
- 2 months ago - Leqembi included in China's commercial insurance innovative drug list - PRNewsWire
- 2 months ago - New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment - PRNewsWire
- 2 months ago - Eisai Announces Filing Of New Drug Application For Leqembi In Japan - Nasdaq
- 2 months ago - New data on lecanemab to be presented at CTAD conference - PRNewsWire
- 2 months ago - BioArctic AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Leqembi® approved for IV maintenance treatment in the United Kingdom - PRNewsWire
- 2 months ago - BioArctic AB (publ) (BRCTF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioArctic AB (BRCTF) Q3 2025 Earnings Call Highlights: Strategic Partnerships and R&D Drive ... - GuruFocus